Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

NCT04470674 is registered in ClinicalTrials.gov with Shirish M Gadgeel as lead sponsor.

NCT NCT04470674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04470674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
Lead sponsor
Shirish M Gadgeel
Phase
Phase 2
Overall status
Withdrawn
Start date
April 6, 2021
Completion date
June 8, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kras activating mutation, lung cancer, non-small cell lung cancer, pd-l1 gene mutation